Natera has enrolled the first patients in a randomized, Signatera-guided interventional trial in advanced melanoma (NCT07504796), testing whether molecular residual disease (MRD) detection can trigger treatment escalation before radiographic progression. NYU Langone Health sponsors the multi-center study, announced from Natera's Austin, Texas headquarters.

The trial targets a defined clinical problem. For patients with advanced or metastatic melanoma, the current standard of care is combination immunotherapy continued until clinical progression. The study aims to identify patients who need earlier intervention by detecting persistent MRD via circulating tumor DNA (ctDNA) prior to radiographic evidence of disease progression.

How does the study design work?

The design hinges on an early treatment-timepoint biopsy of ctDNA. After six weeks of first-line treatment with nivolumab plus relatlimab, patients who test Signatera-positive but show no radiographic progression undergo randomization into one of two arms:

• Continuation of first-line treatment until clinical progression
• Intensification of first-line treatment with the addition of ipilimumab

The primary endpoint is progression-free survival. That choice positions the study to measure directly whether molecularly guided escalation delays progression, rather than merely whether ctDNA status predicts outcomes observationally.

What does MRD positivity mean for melanoma management?

The principal investigator frames the study as a departure from reactive practice. "This trial takes a more proactive therapeutic approach from the standard of care, which is to treat with immunotherapy until evidence of radiographic progression," said Janice M. Mehnert, M.D., principal investigator of the study. "By using Signatera to identify patients who do not clear ctDNA early in the treatment regimen, we can act sooner to escalate therapies for those who need it as we aim to improve outcomes."

The mechanism is straightforward: patients whose ctDNA has not cleared six weeks into nivolumab-relatlimab carry persistent molecular disease that standard imaging cannot yet see. Randomizing only this ctDNA-positive subgroup isolates the question of whether adding ipilimumab at that point improves outcomes over waiting for radiographic progression.

Could the results change practice patterns?

Natera positions the trial as a step toward altering clinical management. "We are pleased to collaborate with NYU Langone Health on this important trial in melanoma," said Michael Krainock, M.D., Ph.D., MBA, medical director, oncology, Natera. "By integrating Signatera into the trial design, we hope to improve patient selection for therapy escalation – distinguishing those who may be able to continue their current treatment without disease progression from others who need more intensified therapy. If the results are positive, this could be an important step toward changing clinical practice patterns in how we manage melanoma."

For dermatologists and oncology teams managing advanced melanoma, the trial addresses a familiar surveillance gap: imaging detects progression late, while ctDNA assays can flag molecular persistence weeks earlier. Signatera, Natera's tumor-informed ctDNA assay, is already supported by the company's broader publication record — Natera states its tests are backed by more than 400 peer-reviewed publications demonstrating performance across indications.

The company runs CLIA-certified, CAP-accredited laboratories in Austin, Texas and San Carlos, California, with an additional site in Boulder, Colorado operated through its Foresight Diagnostics subsidiary.

Manufacturer statements about practice change remain prospective; no efficacy data from the trial exist yet, and the primary endpoint — progression-free survival — will take time to mature. If ctDNA-guided escalation at week six proves superior to treating until radiographic progression, the study could give melanoma clinicians a molecular trigger for intensifying immunotherapy in a disease where timing of escalation is currently guesswork anchored to imaging.